Dapagliflozin
Amber level 0
Brand:
Nice TA:
679
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
1.1 Dapagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
- angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
- sacubitril valsartan, with beta blockers, and, if tolerated, MRAs.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: